STERIS plc provides infection prevention and other procedural products and services worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$235.36|
|52 Week High||US$170.36|
|52 Week Low||US$237.27|
|1 Month Change||6.88%|
|3 Month Change||9.84%|
|1 Year Change||26.98%|
|3 Year Change||118.27%|
|5 Year Change||254.67%|
|Change since IPO||11,311.39%|
Recent News & Updates
STERIS' (NYSE:STE) Dividend Will Be Increased To US$0.43
STERIS plc ( NYSE:STE ) will increase its dividend on the 24th of September to US$0.43. This takes the annual payment...
|STE||US Medical Equipment||US Market|
Return vs Industry: STE exceeded the US Medical Equipment industry which returned 23.1% over the past year.
Return vs Market: STE underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: STE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: STE's weekly volatility (3%) has been stable over the past year.
About the Company
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
STERIS Fundamentals Summary
|STE fundamental statistics|
Is STE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STE income statement (TTM)|
|Cost of Revenue||US$1.90b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 02, 2021
|Earnings per share (EPS)||2.87|
|Net Profit Margin||8.39%|
How did STE perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Is STERIS undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: STE ($235.37) is trading above our estimate of fair value ($127.07)
Significantly Below Fair Value: STE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: STE is poor value based on its PE Ratio (82.1x) compared to the US Medical Equipment industry average (49.9x).
PE vs Market: STE is poor value based on its PE Ratio (82.1x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: STE is poor value based on its PEG Ratio (4.5x)
Price to Book Ratio
PB vs Industry: STE is good value based on its PB Ratio (3.6x) compared to the US Medical Equipment industry average (4.3x).
How is STERIS forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STE's forecast earnings growth (18.4% per year) is above the savings rate (2%).
Earnings vs Market: STE's earnings (18.4% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: STE's earnings are forecast to grow, but not significantly.
Revenue vs Market: STE's revenue (8.9% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: STE's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STE's Return on Equity is forecast to be low in 3 years time (12.8%).
How has STERIS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STE has a large one-off loss of $199.0M impacting its June 30 2021 financial results.
Growing Profit Margin: STE's current net profit margins (8.4%) are lower than last year (13.7%).
Past Earnings Growth Analysis
Earnings Trend: STE's earnings have grown significantly by 21.9% per year over the past 5 years.
Accelerating Growth: STE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: STE had negative earnings growth (-30.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (36.1%).
Return on Equity
High ROE: STE's Return on Equity (4.3%) is considered low.
How is STERIS's financial position?
Financial Position Analysis
Short Term Liabilities: STE's short term assets ($2.0B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: STE's short term assets ($2.0B) do not cover its long term liabilities ($4.4B).
Debt to Equity History and Analysis
Debt Level: STE's debt to equity ratio (55.1%) is considered high.
Reducing Debt: STE's debt to equity ratio has increased from 50.9% to 55.1% over the past 5 years.
Debt Coverage: STE's debt is not well covered by operating cash flow (18%).
Interest Coverage: STE's interest payments on its debt are well covered by EBIT (14.6x coverage).
What is STERIS current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: STE's dividend (0.73%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.28%).
High Dividend: STE's dividend (0.73%) is low compared to the top 25% of dividend payers in the US market (3.48%).
Stability and Growth of Payments
Stable Dividend: STE's dividends per share have been stable in the past 10 years.
Growing Dividend: STE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.4%), STE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: STE's dividends in 3 years are forecast to be well covered by earnings (20.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Carestio (48 yo)
Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD2.91M) is below average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: Dan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: STE's management team is considered experienced (2.2 years average tenure).
Experienced Board: STE's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: STE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.
STERIS plc's employee growth, exchange listings and data sources
- Name: STERIS plc
- Ticker: STE
- Exchange: NYSE
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$23.479b
- Shares outstanding: 99.76m
- Website: https://www.steris.com
Number of Employees
- STERIS plc
- 70 Sir John Rogerson’s Quay
- Dublin 2
- Co. Dublin
- D02 R296
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:30|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.